Nanexa (NANEXA) Stock Overview
A pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
NANEXA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Nanexa AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.25 |
| 52 Week High | SEK 3.15 |
| 52 Week Low | SEK 0.70 |
| Beta | 1.87 |
| 1 Month Change | -14.93% |
| 3 Month Change | 68.67% |
| 1 Year Change | 127.73% |
| 3 Year Change | 0% |
| 5 Year Change | -78.87% |
| Change since IPO | -77.01% |
Recent News & Updates
Recent updates
19,9% Novo Nordisk ownership on a small swedish biotech - could this be a significant technology?
Nanexa AB is a Swedish pharmaceutical company that specializes in drug delivery systems. Here's a brief overview of its corporate history, ownership, focus, and potential:Corporate HistoryNanexa was fHow Much Does Nanexa's (STO:NANEXA) CEO Make?
Dec 09
Shareholder Returns
| NANEXA | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 3.0% | -2.2% | 0.03% |
| 1Y | 127.7% | -12.7% | -3.6% |
Return vs Industry: NANEXA exceeded the Swedish Medical Equipment industry which returned -11% over the past year.
Return vs Market: NANEXA exceeded the Swedish Market which returned -3% over the past year.
Price Volatility
| NANEXA volatility | |
|---|---|
| NANEXA Average Weekly Movement | 13.5% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in SE Market | 13.6% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: NANEXA's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: NANEXA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 13 | David Westberg | nanexa.com |
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a depot drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a depot drug from lenalidomide for the treatment of multiple myeloma.
Nanexa AB (publ) Fundamentals Summary
| NANEXA fundamental statistics | |
|---|---|
| Market cap | SEK 347.55m |
| Earnings (TTM) | -SEK 31.07m |
| Revenue (TTM) | SEK 40.31m |
Is NANEXA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANEXA income statement (TTM) | |
|---|---|
| Revenue | SEK 40.31m |
| Cost of Revenue | SEK 15.42m |
| Gross Profit | SEK 24.88m |
| Other Expenses | SEK 55.95m |
| Earnings | -SEK 31.07m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 27, 2025
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 61.73% |
| Net Profit Margin | -77.08% |
| Debt/Equity Ratio | 23.2% |
How did NANEXA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/21 12:42 |
| End of Day Share Price | 2025/07/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nanexa AB (publ) is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gonzalo Artiach Castanon | ABG Sundal Collier Sponsored |
| Fredrik Thor | Redeye |